You are here: Industry Insights > Mylan

News List

Mylan generic of lung cancer drug Alimta approved europeanpharmaceuticalreview
September 04, 2019
Mylan NV’s generic version Eli Lilly and Co’s lung cancer drug, Alimta, has been given tentative approval by the FDA.
Novo Nordisk files lawsuit against Mylan for generic application europeanpharmaceuticalreview
August 27, 2019
The two pharmaceutical companies are facing a legal battle after Mylan filed a new drug application for a generic of Novo Nordisk’s Victoza.
Mylan and Upjohn Join Forces contractpharma
August 05, 2019
Creates new global pharma company; revenues expected in the $20bn range.
Biocon, Mylan launch Ogivri in Australia biospectrumasia
August 04, 2019
Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme (PBS).
Mylan and Biocon launch first Trastuzumab Biosimilar, Ogivri, in Australia expresspharma
August 02, 2019
Biocon and Mylan NV have announced the launch of Ogivri (trastuzumab), a biosimilar to Herceptin (trastuzumab), in Australia for treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcin
Mylan, which bought Novartis CF drugs, circles back for the manufacturing assets fiercepharma
August 01, 2019
Mylan has spent more than $460 million buying Novartis cystic fibrosis products. Now, it wants the plant that makes them.
Biocon, Mylan launch first Trastuzumab Biosimilar Ogivri in Australia biospectrumasia
August 01, 2019
Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme (PBS).
Mylan to merge with Pfizer’s off-patent drugs unit Upjohn pharmaceutical-technology
July 31, 2019
Mylan has signed a definitive agreement to combine with Pfizer’s off-patent branded and generic medicines division Upjohn to form a new pharmaceutical company.
Mylan CEO Bresch set to exit after years of controversy—and one last big deal fiercepharma
July 30, 2019
During Mylan CEO Heather Bresch's 28-year stint there, the company has utterly transformed into a generics giant—and courted controversy along the way.
Pfizer's big split is finally here, thanks to a giant generics merger with Mylan biospectrumasia
July 30, 2019
Looks like consumer health isn’t the only franchise Pfizer is looking to shed. In a payoff for years of split-up talk, the pharma giant's got hive-off plans for its generics business, too.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page